263 related articles for article (PubMed ID: 8096703)
1. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group.
Cooper DA; Pehrson PO; Pedersen C; Moroni M; Oksenhendler E; Rozenbaum W; Clumeck N; Faber V; Stille W; Hirschel B
AIDS; 1993 Feb; 7(2):197-207. PubMed ID: 8096703
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group.
Cooper DA; Pedersen C; Aiuti F; Vilde JL; Ruhnke M; Pehrson PO; Clumeck N; Farthing C; Lüthy R; Doherty RR
AIDS; 1991 Aug; 5(8):933-43. PubMed ID: 1777174
[TBL] [Abstract][Full Text] [Related]
3. The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.
Pedersen C; Cooper DA; Brun-Vézinet F; Doherty R; Skinhøj P; Pérol Y; Lüthy R; Leibowitch J; Habermehl KO; Varnier OE
AIDS; 1992 Aug; 6(8):821-5. PubMed ID: 1418778
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: factors influencing development of AIDS, survival and drug intolerance. Australian Zidovudine Study Group.
Swanson CE; Tindall B; Cooper DA
AIDS; 1994 May; 8(5):625-34. PubMed ID: 8060543
[TBL] [Abstract][Full Text] [Related]
7. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.
Spector SA; Gelber RD; McGrath N; Wara D; Barzilai A; Abrams E; Bryson YJ; Dankner WM; Livingston RA; Connor EM
N Engl J Med; 1994 Nov; 331(18):1181-7. PubMed ID: 7935655
[TBL] [Abstract][Full Text] [Related]
9. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group.
Merigan TC; Amato DA; Balsley J; Power M; Price WA; Benoit S; Perez-Michael A; Brownstein A; Kramer AS; Brettler D
Blood; 1991 Aug; 78(4):900-6. PubMed ID: 1831059
[TBL] [Abstract][Full Text] [Related]
10. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.
Fischl MA; Richman DD; Causey DM; Grieco MH; Bryson Y; Mildvan D; Laskin OL; Groopman JE; Volberding PA; Schooley RT
JAMA; 1989 Nov; 262(17):2405-10. PubMed ID: 2677429
[TBL] [Abstract][Full Text] [Related]
11. Didanosine therapy in patients intolerant of or failing zidovudine therapy.
Rathbun RC; Martin ES
Ann Pharmacother; 1992 Nov; 26(11):1347-51. PubMed ID: 1362093
[TBL] [Abstract][Full Text] [Related]
12. Phase II, randomized, open-label, community-based trial to compare the safety and activity of combination therapy with recombinant interferon-alpha2b and zidovudine versus zidovudine alone in patients with asymptomatic to mildly symptomatic HIV infection. HIV Protocol C91-253 Study Team.
Krown SE; Aeppli D; Balfour HH
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Mar; 20(3):245-54. PubMed ID: 10077172
[TBL] [Abstract][Full Text] [Related]
13. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee.
Lancet; 1994 Apr; 343(8902):871-81. PubMed ID: 7908356
[TBL] [Abstract][Full Text] [Related]
14. Preliminary report of a multicentre study of zidovudine plus or minus acyclovir in patients with acquired immune deficiency syndrome or acquired immune deficiency syndrome-related complex.
Fiddian AP
J Infect; 1989 Jan; 18 Suppl 1():79-80. PubMed ID: 2644364
[No Abstract] [Full Text] [Related]
15. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.
Gallant JE; Moore RD; Keruly J; Richman DD; Chaisson RE
J Infect Dis; 1995 Aug; 172(2):346-52. PubMed ID: 7622876
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
[TBL] [Abstract][Full Text] [Related]
17. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine. German ddI Trial Group.
Jablonowski H; Arasteh K; Staszewski S; Ruf B; Stellbrink HJ; Schrappe M; Stoehr A; Haase W; Schomaker U; von Eisenhart Rothe B
AIDS; 1995 May; 9(5):463-9. PubMed ID: 7639971
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.
Fernández-Cruz E; Lang JM; Frissen J; Furner V; Châteauvert M; Boucher CA; Dowd P; Stevens J
AIDS; 1995 Sep; 9(9):1025-35. PubMed ID: 8527074
[TBL] [Abstract][Full Text] [Related]
19. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte-macrophage colony-stimulating factor ameliorates zidovudine-induced neutropenia in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex.
Levine JD; Allan JD; Tessitore JH; Falcone N; Galasso F; Israel RJ; Groopman JE
Blood; 1991 Dec; 78(12):3148-54. PubMed ID: 1742482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
